ARCHIVES

Phase III Afatinib Trial Met Primary Endpoint In Stage IIIb or IV Cancer with EGFR Mutation

This article is from The Cancer Letter archive.

Vol. 35 No. 6 | June 29, 2012

Download PDF Visit The Full Archive

Related Articles

ACS Urges Practice Of Insurance Exclusion End Under Reform

February 5, 1993

Sequestration Hurts Kids with Cancer

March 15, 2013

Brain Gliomas Progress When Gene Function Is Lost

April 25, 2003

FDA Approves Abraxane And Alimta for NSCLC

October 26, 2012

In Brief: VP-16 NDA Approved By FDA Only For Refractory Testicular Cancer; Removed From Group C List

December 2, 1983

In Brief: Henney To Leave NCI For Kansas; Dan Longo Heads BRMP; DeVita To Receive Nervi Award

May 10, 1985